



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Deep Brain Stimulation

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)

Policy Number: 473

BCBSA Reference Number: 7.01.63 (For Plans internal use only)

Related Policies

- Spinal Cord and Dorsal Root Ganglion Stimulation, #[472](#)
- Responsive Neurostimulation for the Treatment of Refractory Partial Epilepsy, #[716](#)
- Transcranial Magnetic Stimulation as a Treatment of Depression, #[297](#)
- Vagus Nerve Stimulation, #[474](#)

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

Unilateral deep brain stimulation of the thalamus may be considered **MEDICALLY NECESSARY** in patients with disabling, medically unresponsive tremor due to essential tremor or Parkinson disease.

Bilateral deep brain stimulation of the thalamus may be considered **MEDICALLY NECESSARY** in patients with disabling, medically unresponsive tremor in both upper limbs due to essential tremor or Parkinson disease.

Unilateral or bilateral deep brain stimulation of the globus pallidus or subthalamic nucleus may be considered **MEDICALLY NECESSARY** in the following patients:

- Those with Parkinson disease with ALL of the following:
 - A good response to levodopa, AND
 - Motor complications not controlled by pharmacologic therapy; AND
 - one of the following:
 - A minimum score of 30 points on the motor portion of the Unified Parkinson Disease Rating Scale when the patient has been without medication for approximately 12 hours, OR
 - Parkinson disease for at least 4 years
- Patients older than 7 years with chronic, intractable (drug refractory) primary dystonia, including generalized and/or segmental dystonia, hemidystonia, and cervical dystonia (torticollis).

Deep brain stimulation for other movement disorders, including but not limited to tardive dyskinesia multiple sclerosis, and post-traumatic dyskinesia, is considered **INVESTIGATIONAL**.

Deep brain stimulation for the treatment of chronic cluster headaches is considered [INVESTIGATIONAL](#).

Deep brain stimulation for the treatment of other psychiatric or neurologic disorders, including but not limited to epilepsy, Tourette syndrome, depression, obsessive-compulsive disorder, anorexia nervosa, alcohol addiction, Alzheimer disease, and chronic pain, is considered [INVESTIGATIONAL](#).

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	This procedure is performed in the inpatient setting.
Commercial PPO and Indemnity	This procedure is performed in the inpatient setting.

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity:

CPT Codes

CPT codes:	Code Description
61863	Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (eg, thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), without use of intraoperative microelectrode recording; first array
61864	Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (eg, thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), without use of intraoperative microelectrode recording; each additional array (List separately in addition to primary procedure)
61867	Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (eg, thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), with use of intraoperative microelectrode recording; first array
61868	Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (eg, thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), with use of intraoperative microelectrode recording; each additional array

Description

Deep Brain Stimulation

Deep brain stimulation involves the stereotactic placement of an electrode into the brain (ie, hypothalamus, thalamus, globus pallidus, or subthalamic nucleus). The electrode is initially attached to a temporary transcutaneous cable for short-term stimulation to validate treatment effectiveness. Several days later, the patient returns for permanent subcutaneous surgical implantation of the cable and a radiofrequency-coupled or battery-powered programmable stimulator. The electrode is typically implanted unilaterally on the side corresponding to the most severe symptoms. However, use of bilateral stimulation using two electrode arrays has also been investigated in patients with bilateral, severe symptoms. After implantation, noninvasive programming of the neurostimulator can be adjusted to the patient's symptoms. This feature may be important for patients with Parkinson disease, whose disease may progress over time, requiring different neurostimulation parameters. Setting the optimal neurostimulation parameters may involve the balance between optimal symptom control and appearance of adverse effects of neurostimulation, such as dysarthria, disequilibrium, or involuntary movements.

Summary

Deep brain stimulation involves the stereotactic placement of an electrode into a central nervous system nucleus (eg, hypothalamus, thalamus, globus pallidus, subthalamic nucleus). Deep brain stimulation is used as an alternative to permanent neuroablative procedures for control of essential tremor and Parkinson disease. Deep brain stimulation is also being evaluated for the treatment of a variety of other neurologic and psychiatric disorders.

For individuals who have essential tremor or tremor in Parkinson disease who receive deep brain stimulation of the thalamus, the evidence includes a systematic review and case series. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. The systematic review (a TEC Assessment) concluded that there was sufficient evidence that deep brain stimulation of the thalamus results in clinically significant tremor suppression and that outcomes after deep brain stimulation were at least as good as thalamotomy. Subsequent studies reporting long-term follow-up have supported the conclusions of the TEC Assessment and found that tremors were effectively controlled five to six years after deep brain stimulation. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have symptoms (eg, speech, motor fluctuations) associated with Parkinson disease (advanced or >4 years in duration with early motor symptoms) who receive deep brain stimulation of the globus pallidus interna or subthalamic nucleus, the evidence includes randomized controlled trials (RCTs) and systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. One of the systematic reviews (a TEC Assessment) concluded that studies evaluating deep brain stimulation of the globus pallidus interna or subthalamic nucleus have consistently demonstrated clinically significant improvements in outcomes (eg, neurologic function). Other systematic reviews have also found significantly better outcomes after deep brain stimulation than after a control intervention. An RCT in patients with levodopa-responsive Parkinson disease of at least four years in duration and uncontrolled motor symptoms found that quality of life at two years was significantly higher when deep brain stimulation was provided in addition to medical therapy. Meta-analyses of RCTs comparing deep brain stimulation of the globus pallidus interna with deep brain stimulation of the subthalamic nucleus have reported mixed findings and have not shown that one type of stimulation is clearly superior to the other. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have primary dystonia who receive deep brain stimulation of the globus pallidus interna or subthalamic nucleus, the evidence includes systematic reviews, RCTs, and case series. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. A pooled analysis of 24 studies, mainly uncontrolled, found improvements in motor scores and disability scores after 6 months and at last follow-up (mean, 32 months). Both double-blind RCTs found that severity scores improved more after active than after sham stimulation. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have tardive dyskinesia or tardive dystonia who receive deep brain stimulation, the evidence includes an RCT and case series. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Few studies were identified, and they had small sample sizes (range, 9-19 patients). The RCT did not report statistically significant improvement in the dystonia severity outcomes or the secondary outcomes related to disability and quality of life but may have been under-powered. Additional studies, especially RCTs or other controlled studies, are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have epilepsy who receive deep brain stimulation, the evidence includes systematic reviews, RCTs and many observational studies. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Two RCTs with more than 15 patients were identified. The larger RCT evaluated anterior thalamic nucleus deep brain stimulation and reported that deep brain stimulation had a positive impact on seizure frequency during some parts of the blinded trial phase but not others, and a substantial number of adverse events (in >30% of patients). There were no differences between groups in 50% responder rates, Liverpool Seizure Severity Scale, or Quality of Life in Epilepsy scores. A 7-year open-label follow-up of the RCT included 66% of implanted patients; reasons for missing data were primarily related to adverse events or dissatisfaction with the device. Reduction in seizure frequency continued to improve during follow-up among the patients who continued follow-up. The smaller RCT (n=16) showed a benefit with deep brain stimulation. Many small observational studies reported fewer seizures compared with baseline, however, without control groups, interpretation of these results is limited. Additional trials are required to determine the impact of deep brain stimulation on patient outcomes. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have Tourette syndrome who receive deep brain stimulation, the evidence includes observational studies, RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Two RCTs with 15 or more patients have been reported. One RCT found differences in severity of Tourette syndrome for active vs sham at three months while the other RCT did not. Neither study demonstrated improvements in comorbid symptoms of obsessive-compulsive disorder or depression. Both studies reported high rates of serious adverse events. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have cluster headaches or facial pain who receive deep brain stimulation, the evidence includes a randomized crossover study and case series. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. In the randomized study, the between-group difference in response rates did not differ significantly between active and sham stimulation phases. Additional RCTs or controlled studies are needed. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have treatment resistant depression who receive deep brain stimulation, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. A number of case series and several prospective controlled trials evaluating deep brain stimulation in patients with have been published. Two RCTs of deep brain stimulation in the subgenual cingulate cortex and ventral striatum/ventral capsule were terminated for futility. Another RCT of stimulation of the same brain area (ventral striatum/ventral capsule) did not find a statistically significant difference between groups in the primary outcome (clinical response), and adverse psychiatric events occurred more frequently in the treatment group than in the control group. More recently, a controlled crossover trial randomized patients to sham or active stimulation of the anterior limb of the internal capsule after a year of open-label stimulation. There was a greater reduction in symptom scores after active stimulation, but only in patients who were responders in the open-label phase. Stimulation of the subcallosal (subgenual) cingulate was evaluated in a 2019 sham-controlled within-subject study that found prolonged response in 50% of patients and remission in 30% of patients with treatment resistant depression. Deep brain stimulation for patients with major depressive disorder who have failed all other treatment options is an active area of research, but the brain regions that might prove to be effective for treatment resistant depression have yet to be established. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have obsessive-compulsive disorder who receive deep brain stimulation, the evidence includes RCTs and systematic reviews. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. Among the RCTs on deep brain stimulation for obsessive-compulsive disorder, only one has reported the outcome of greatest clinical interest (therapeutic response rate), and that trial did not find a statistically significant benefit for deep brain stimulation compared with sham treatment. The evidence is insufficient to determine the effects of the technology on health.

For individuals who have multiple sclerosis who receive deep brain stimulation, the evidence includes an RCT. Relevant outcome are symptoms, functional outcomes, quality of life, and treatment-related morbidity. One RCT with ten multiple sclerosis patients is insufficient evidence on which to draw conclusions about the efficacy of deep brain stimulation in this population. Additional trials are required. The evidence is insufficient to determine the effects of the technology on health outcomes.

For individuals who have anorexia nervosa, alcohol addiction, Alzheimer disease, Huntington disease, or chronic pain who receive deep brain stimulation, the evidence includes case series. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. RCTs are needed to evaluate the efficacy of deep brain stimulation for these conditions. The evidence is insufficient to determine the effects of the technology on health outcomes.

Policy History

Date	Action
6/2022	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
5/2021	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
1/2021	Medicare information removed. See MP #132 Medicare Advantage Management for local coverage determination and national coverage determination reference.
6/2020	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
5/2019	Annual policy review. Description, summary, and references updated. Policy statements unchanged.
3/2019	Prior authorization information clarified.
1/2019	Clarified coding changes. Prior authorization clarified. This procedure is primarily performed in the inpatient setting.
9/2017	Annual policy review. Unilateral or bilateral deep brain stimulation of the globus pallidus or subthalamic nucleus revised to include "OR Parkinson disease for at least 4 years" to medically necessary criteria. New investigational indications described. Clarified coding information. Effective 9/1/2017.
6/2016	Annual policy review. Added "upper" to medically necessary statement on DBS for medically unresponsive tremor due to essential tremor or Parkinson disease to clarify that the statement refers to both upper limbs. 6/1/2016
4/2015	Annual policy review. New medically necessary indications described. Effective 4/1/2015.
6/2014	Updated Coding section with ICD10 procedure and diagnosis codes, effective 10/2015.
12/2013	Annual policy review. New investigational indications described. Effective 12/1/2013. Removed HCPCS codes L8680, L8685-L8688 as they do not meet the intent of the policy
10/2013	Removed CPT codes 61880, 61885, 61886, 61888, 95970 and diagnosis codes 333.6, 333.83, 333.89 & 723.5 as they do not apply to the policy.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
4/2011	Annual policy review. No changes to policy statements.
1/2011	Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements.
4/2010	Annual policy review. Changes to policy statements.

1/2010	Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements.
3/2009	Annual policy review. No changes to policy statements.
1/2009	Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements.
1/2008	Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements.
7/2007	Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements.
4/2007	Annual policy review. Changes to policy statements.
2/2007	Reviewed - Medical Policy Group - Psychiatry and Ophthalmology. No changes to policy statements.
1/2007	Reviewed - Medical Policy Group - Neurology and Neurosurgery. No changes to policy statements.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Blue Cross and Blue Shield Technology Evaluation Center. Deep brain stimulation of the thalamus for tremor. TEC Assessment. 1997;Volume 12:Tab 20.
2. Schuurman PR, Bosch DA, Merkus MP, et al. Long-term follow-up of thalamic stimulation versus thalamotomy for tremor suppression. *Mov Disord*. Jun 15 2008; 23(8): 1146-53. PMID 18442104
3. Hariz MI, Krack P, Alesch F, et al. Multicentre European study of thalamic stimulation for parkinsonian tremor: a 6 year follow-up. *J Neurol Neurosurg Psychiatry*. Jun 2008; 79(6): 694-9. PMID 17898034
4. Putzke JD, Uitti RJ, Obwegeser AA, et al. Bilateral thalamic deep brain stimulation: midline tremor control. *J Neurol Neurosurg Psychiatry*. May 2005; 76(5): 684-90. PMID 15834027
5. Pahwa R, Lyons KE, Wilkinson SB, et al. Long-term evaluation of deep brain stimulation of the thalamus. *J Neurosurg*. Apr 2006; 104(4): 506-12. PMID 16619653
6. Pollo C, Kaelin-Lang A, Oertel MF, et al. Directional deep brain stimulation: an intraoperative double-blind pilot study. *Brain*. Jul 2014; 137(Pt 7): 2015-26. PMID 24844728
7. Steigerwald F, Muller L, Johannes S, et al. Directional deep brain stimulation of the subthalamic nucleus: A pilot study using a novel neurostimulation device. *Mov Disord*. Aug 2016; 31(8): 1240-3. PMID 27241197
8. Rebelo P, Green AL, Aziz TZ, et al. Thalamic Directional Deep Brain Stimulation for tremor: Spend less, get more. *Brain Stimul*. May 2018; 11(3): 600-606. PMID 29373260
9. Dembek TA, Reker P, Visser-Vandewalle V, et al. Directional DBS increases side-effect thresholds-A prospective, double-blind trial. *Mov Disord*. Oct 2017; 32(10): 1380-1388. PMID 28843009
10. Blue Cross and Blue Shield Technology Evaluation Center. Bilateral deep brain stimulation of the subthalamic nucleus or the globus pallidus interna for treatment of advanced Parkinson's disease. TEC Assessment. 2001;Volume 16:Tab 16.
11. Perestelo-Perez L, Rivero-Santana A, Perez-Ramos J, et al. Deep brain stimulation in Parkinson's disease: meta-analysis of randomized controlled trials. *J Neurol*. Nov 2014; 261(11): 2051-60. PMID 24487826
12. Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. *Mov Disord*. Jun 2006; 21 Suppl 14: S290-304. PMID 16892449
13. Appleby BS, Duggan PS, Regenber A, et al. Psychiatric and neuropsychiatric adverse events associated with deep brain stimulation: A meta-analysis of ten years' experience. *Mov Disord*. Sep 15 2007; 22(12): 1722-8. PMID 17721929

14. Schuepbach WM, Rau J, Knudsen K, et al. Neurostimulation for Parkinson's disease with early motor complications. *N Engl J Med.* Feb 14 2013; 368(7): 610-22. PMID 23406026
15. Sako W, Miyazaki Y, Izumi Y, et al. Which target is best for patients with Parkinson's disease? A meta-analysis of pallidal and subthalamic stimulation. *J Neurol Neurosurg Psychiatry.* Sep 2014; 85(9): 982-6. PMID 24444854
16. Combs HL, Folley BS, Berry DT, et al. Cognition and Depression Following Deep Brain Stimulation of the Subthalamic Nucleus and Globus Pallidus Pars Internus in Parkinson's Disease: A Meta-Analysis. *Neuropsychol Rev.* Dec 2015; 25(4): 439-54. PMID 26459361
17. Tan ZG, Zhou Q, Huang T, et al. Efficacies of globus pallidus stimulation and subthalamic nucleus stimulation for advanced Parkinson's disease: a meta-analysis of randomized controlled trials. *Clin Interv Aging.* 2016; 11: 777-86. PMID 27382262
18. Wang JW, Zhang YQ, Zhang XH, et al. Cognitive and Psychiatric Effects of STN versus GPi Deep Brain Stimulation in Parkinson's Disease: A Meta-Analysis of Randomized Controlled Trials. *PLoS One.* 2016; 11(6): e0156721. PMID 27248139
19. Xie CL, Shao B, Chen J, et al. Effects of neurostimulation for advanced Parkinson's disease patients on motor symptoms: A multiple-treatments meta-analysis of randomized controlled trials. *Sci Rep.* May 04 2016; 6: 25285. PMID 27142183
20. Xu F, Ma W, Huang Y, et al. Deep brain stimulation of pallidal versus subthalamic for patients with Parkinson's disease: a meta-analysis of controlled clinical trials. *Neuropsychiatr Dis Treat.* 2016; 12: 1435-44. PMID 27382286
21. Wong JK, Cauraugh JH, Ho KWD, et al. STN vs. GPi deep brain stimulation for tremor suppression in Parkinson disease: A systematic review and meta-analysis. *Parkinsonism Relat Disord.* Jan 2019; 58: 56-62. PMID 30177491
22. U.S. Food and Drug Administration. Summary of Safety and Probable Benefit. Medtronic Activa Dystonia Therapy. 2003; http://www.accessdata.fda.gov/cdrh_docs/pdf2/H020007b.pdf. Accessed March 18, 2021.
23. Moro E, LeReun C, Krauss JK, et al. Efficacy of pallidal stimulation in isolated dystonia: a systematic review and meta-analysis. *Eur J Neurol.* Apr 2017; 24(4): 552-560. PMID 28186378
24. Rodrigues FB, Duarte GS, Prescott D, et al. Deep brain stimulation for dystonia. *Cochrane Database Syst Rev.* Jan 10 2019; 1: CD012405. PMID 30629283
25. Kupsch A, Benecke R, Muller J, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. *N Engl J Med.* Nov 09 2006; 355(19): 1978-90. PMID 17093249
26. Volkmann J, Mueller J, Deuschl G, et al. Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial. *Lancet Neurol.* Sep 2014; 13(9): 875-84. PMID 25127231
27. Gruber D, Sudmeyer M, Deuschl G, et al. Neurostimulation in tardive dystonia/dyskinesia: A delayed start, sham stimulation-controlled randomized trial. *Brain Stimul.* Nov 2018; 11(6): 1368-1377. PMID 30249417
28. Damier P, Thobois S, Witjas T, et al. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. *Arch Gen Psychiatry.* Feb 2007; 64(2): 170-6. PMID 17283284
29. Gruber D, Trottenberg T, Kivi A, et al. Long-term effects of pallidal deep brain stimulation in tardive dystonia. *Neurology.* Jul 07 2009; 73(1): 53-8. PMID 19564584
30. Pouclet-Courtemanche H, Rouaud T, Thobois S, et al. Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. *Neurology.* Feb 16 2016; 86(7): 651-9. PMID 26791148
31. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia.* Jun 2010; 51(6): 1069-77. PMID 19889013
32. Borghs S, de la Loge C, Cramer JA. Defining minimally important change in QOLIE-31 scores: estimates from three placebo-controlled lacosamide trials in patients with partial-onset seizures. *Epilepsy Behav.* Mar 2012; 23(3): 230-4. PMID 22341962
33. Sprengers M, Vonck K, Carrette E, et al. Deep brain and cortical stimulation for epilepsy. *Cochrane Database Syst Rev.* Jul 18 2017; 7: CD008497. PMID 28718878
34. Li MCH, Cook MJ. Deep brain stimulation for drug-resistant epilepsy. *Epilepsia.* Feb 2018; 59(2): 273-290. PMID 29218702

35. Bouwens van der Vlis TAM, Schijns OEMG, Schaper FLWVJ, et al. Deep brain stimulation of the anterior nucleus of the thalamus for drug-resistant epilepsy. *Neurosurg Rev.* Jun 2019; 42(2): 287-296. PMID 29306976
36. Fisher R, Salanova V, Witt T, et al. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. *Epilepsia.* May 2010; 51(5): 899-908. PMID 20331461
37. Food and Drug Administration. Medtronic DBS System for Epilepsy, Summary of Safety and Effectiveness Data (SSED). Accessed March 18, 2021.
38. Troster AI, Meador KJ, Irwin CP, et al. Memory and mood outcomes after anterior thalamic stimulation for refractory partial epilepsy. *Seizure.* Feb 2017; 45: 133-141. PMID 28061418
39. Cukiert A, Cukiert CM, Burattini JA, et al. Seizure outcome after hippocampal deep brain stimulation in patients with refractory temporal lobe epilepsy: A prospective, controlled, randomized, double-blind study. *Epilepsia.* Oct 2017; 58(10): 1728-1733. PMID 28744855
40. Salanova V, Witt T, Worth R, et al. Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. *Neurology.* Mar 10 2015; 84(10): 1017-25. PMID 25663221
41. Kim SH, Lim SC, Kim J, et al. Long-term follow-up of anterior thalamic deep brain stimulation in epilepsy: A 11-year, single center experience. *Seizure.* Nov 2017; 52: 154-161. PMID 29040867
42. Baldermann JC, Schuller T, Huys D, et al. Deep Brain Stimulation for Tourette-Syndrome: A Systematic Review and Meta-Analysis. *Brain Stimul.* Mar-Apr 2016; 9(2): 296-304. PMID 26827109
43. Frait A, Pal G. Deep Brain Stimulation in Tourette's Syndrome. *Front Neurol.* 2015; 6: 170. PMID 26300844
44. Schrock LE, Mink JW, Woods DW, et al. Tourette syndrome deep brain stimulation: a review and updated recommendations. *Mov Disord.* Apr 2015; 30(4): 448-71. PMID 25476818
45. Servello D, Zekaj E, Saleh C, et al. Sixteen years of deep brain stimulation in Tourette's Syndrome: a critical review. *J Neurosurg Sci.* Jun 2016; 60(2): 218-29. PMID 26788742
46. Piedad JC, Rickards HE, Cavanna AE. What patients with gilles de la tourette syndrome should be treated with deep brain stimulation and what is the best target?. *Neurosurgery.* Jul 2012; 71(1): 173-92. PMID 22407075
47. Wehmeyer L, Schuller T, Kiess J, et al. Target-Specific Effects of Deep Brain Stimulation for Tourette Syndrome: A Systematic Review and Meta-Analysis. *Front Neurol.* 2021; 12: 769275. PMID 34744993
48. Kefalopoulou Z, Zrinzo L, Jahanshahi M, et al. Bilateral globus pallidus stimulation for severe Tourette's syndrome: a double-blind, randomised crossover trial. *Lancet Neurol.* Jun 2015; 14(6): 595-605. PMID 25882029
49. Welter ML, Houeto JL, Thobois S, et al. Anterior pallidal deep brain stimulation for Tourette's syndrome: a randomised, double-blind, controlled trial. *Lancet Neurol.* Aug 2017; 16(8): 610-619. PMID 28645853
50. Martinez-Ramirez D, Jimenez-Shahed J, Leckman JF, et al. Efficacy and Safety of Deep Brain Stimulation in Tourette Syndrome: The International Tourette Syndrome Deep Brain Stimulation Public Database and Registry. *JAMA Neurol.* Mar 01 2018; 75(3): 353-359. PMID 29340590
51. International Headache Society. International Classification of Headache Disorders. 2018; <https://www.ichd-3.org>. Accessed March 18, 2021.
52. Fontaine D, Lazorthes Y, Mertens P, et al. Safety and efficacy of deep brain stimulation in refractory cluster headache: a randomized placebo-controlled double-blind trial followed by a 1-year open extension. *J Headache Pain.* Feb 2010; 11(1): 23-31. PMID 19936616
53. Bussone G, Franzini A, Proietti Cecchini A, et al. Deep brain stimulation in craniofacial pain: seven years' experience. *Neurol Sci.* May 2007; 28 Suppl 2: S146-9. PMID 17508162
54. Broggi G, Franzini A, Leone M, et al. Update on neurosurgical treatment of chronic trigeminal autonomic cephalalgias and atypical facial pain with deep brain stimulation of posterior hypothalamus: results and comments. *Neurol Sci.* May 2007; 28 Suppl 2: S138-45. PMID 17508161
55. Hitti FL, Yang AI, Cristancho MA, et al. Deep Brain Stimulation Is Effective for Treatment-Resistant Depression: A Meta-Analysis and Meta-Regression. *J Clin Med.* Aug 30 2020; 9(9). PMID 32872572
56. Wu Y, Mo J, Sui L, et al. Deep Brain Stimulation in Treatment-Resistant Depression: A Systematic Review and Meta-Analysis on Efficacy and Safety. *Front Neurosci.* 2021; 15: 655412. PMID 33867929

57. Dougherty DD, Rezai AR, Carpenter LL, et al. A Randomized Sham-Controlled Trial of Deep Brain Stimulation of the Ventral Capsule/Ventral Striatum for Chronic Treatment-Resistant Depression. *Biol Psychiatry*. Aug 15 2015; 78(4): 240-8. PMID 25726497
58. Bergfeld IO, Mantione M, Hoogendoorn ML, et al. Deep Brain Stimulation of the Ventral Anterior Limb of the Internal Capsule for Treatment-Resistant Depression: A Randomized Clinical Trial. *JAMA Psychiatry*. May 01 2016; 73(5): 456-64. PMID 27049915
59. Crowell AL, Riva-Posse P, Holtzheimer PE, et al. Long-Term Outcomes of Subcallosal Cingulate Deep Brain Stimulation for Treatment-Resistant Depression. *Am J Psychiatry*. Nov 01 2019; 176(11): 949-956. PMID 31581800
60. Mar-Barrutia L, Real E, Segalas C, et al. Deep brain stimulation for obsessive-compulsive disorder: A systematic review of worldwide experience after 20 years. *World J Psychiatry*. Sep 19 2021; 11(9): 659-680. PMID 34631467
61. Raviv N, Staudt MD, Rock AK, et al. A Systematic Review of Deep Brain Stimulation Targets for Obsessive Compulsive Disorder. *Neurosurgery*. Nov 16 2020; 87(6): 1098-1110. PMID 32615588
62. Kisely S, Hall K, Siskind D, et al. Deep brain stimulation for obsessive-compulsive disorder: a systematic review and meta-analysis. *Psychol Med*. Dec 2014; 44(16): 3533-42. PMID 25066053
63. Brandmeir NJ, Murray A, Cheyuo C, et al. Deep Brain Stimulation for Multiple Sclerosis Tremor: A Meta-Analysis. *Neuromodulation*. Jun 2020; 23(4): 463-468. PMID 31755637
64. Deer TR, Falowski S, Arle JE, et al. A Systematic Literature Review of Brain Neurostimulation Therapies for the Treatment of Pain. *Pain Med*. Nov 07 2020; 21(7): 1415-1420. PMID 32034418
65. Gratwicke J, Zrinzo L, Kahan J, et al. Bilateral nucleus basalis of Meynert deep brain stimulation for dementia with Lewy bodies: A randomised clinical trial. *Brain Stimul*. Jul 2020; 13(4): 1031-1039. PMID 32334074
66. Zesiewicz TA, Elble RJ, Louis ED, et al. Evidence-based guideline update: treatment of essential tremor: report of the Quality Standards subcommittee of the American Academy of Neurology. *Neurology*. Nov 08 2011; 77(19): 1752-5. PMID 22013182
67. Zesiewicz TA, Elble R, Louis ED, et al. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. Jun 28 2005; 64(12): 2008-20. PMID 15972843
68. Rughani A, Schwalb JM, Sidiropoulos C, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Subthalamic Nucleus and Globus Pallidus Internus Deep Brain Stimulation for the Treatment of Patients With Parkinson's Disease: Executive Summary. *Neurosurgery*. Jun 01 2018; 82(6): 753-756. PMID 29538685
69. Bhidayasiri R, Jitkriksadakul O, Friedman JH, et al. Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm. *J Neurol Sci*. Jun 15 2018; 389: 67-75. PMID 29454493
70. Pringsheim T, Okun MS, Muller-Vahl K, et al. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. *Neurology*. May 07 2019; 92(19): 896-906. PMID 31061208
71. Staudt MD, Pouratian N, Miller JP, et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines for Deep Brain Stimulations for Obsessive-Compulsive Disorder: Update of the 2014 Guidelines. *Neurosurgery*. Mar 15 2021; 88(4): 710-712. PMID 33559678
72. National Institute for Health and Care Excellence (NICE). Deep brain stimulation for tremor and dystonia (excluding Parkinson's disease) [IPG188]. 2006; <https://www.nice.org.uk/guidance/ipg188>. Accessed March 3, 2022.
73. National Institute for Health and Care Excellence (NICE). Deep brain stimulation for refractory chronic pain syndromes (excluding headache) [IPG382]. 2011; <http://guidance.nice.org.uk/IPG382>. Accessed March 3, 2022.
74. National Institute for Health and Care Excellence (NICE). Deep brain stimulation for intractable trigeminal autonomic cephalalgias [IPG381]. 2011; <http://www.nice.org.uk/IPG381>. Accessed March 3, 2022.
75. National Institute for Health and Care Excellence (NICE). Deep brain stimulation for refractory epilepsy [IPG416]. 2020; <https://www.nice.org.uk/guidance/IPG678/chapter/1-Recommendations>. Accessed March 3, 2022.
76. National Institute for Health and Care Excellence (NICE). Deep brain stimulation for Parkinson's disease [IPG19]. 2003; <https://www.nice.org.uk/guidance/ipg19>. Accessed March 3, 2022.

77. Centers for Medicare & Medicaid (CMS). National Coverage Determination (NCD) for Deep Brain Stimulation for Essential Tremor and Parkinson's Disease (160.24). 2003; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=279&ncdver=1&DocID=160.24&bc=gAAAABAAAA&>. Accessed March 18, 2021.